Friday , April 23 2021

Lupine receives EIR from USPDA for her Nagpur setup



New Delhi, Nov. 12 (LTI) firm Lupin received a report from the US Health Regulatory Authority on Monday inspecting his Nagpur facility.

"The United States Food and Drug Administration (USFDA) has conducted a pre-approved review of the 100 mg capsule of phenytoin sodium," Lupine told BSE.

The plant was tested by USFDA in September 2018.

USFDA will provide EDA with a FDA or FDA closure inspection facility.

Lupine Nilesh Gupta: "Successful completion of Nagpur Inspection is optimal development, as we meet international standards and exceed it." Lupine's shares today were 1.64% higher on Rs at 868.20 tenge on BSE.

This is a public announcement from the PTI channel.


Source link

About india